Large study reviews bleeding risks of common cancer drug in japanese patients
NCT ID NCT07527832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of Bevacizumab-Pfizer Biosimilar, a drug used to treat colorectal cancer, by analyzing medical records from 1,000 patients in Japan. Researchers focused on side effects like bleeding, high blood pressure, and kidney problems. The goal was to understand how safe the drug is in everyday hospital use, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?